{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:03:44Z","timestamp":1792451024538,"version":"4.5.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2021,6,1]]},"DOI":"10.1001\/jamainternmed.2021.1154","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T04:26:48Z","timestamp":1618892808000},"page":"808","source":"Crossref","is-referenced-by-count":28,"title":["Association of US Food and Drug Administration Removal of Indications for Use of Oral Quinolones With Prescribing Trends"],"prefix":"10.1001","volume":"181","author":[{"given":"Phuong T.","family":"Tran","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Faculty of Pharmacy, Ho Chi Minh City University of Technology (HUTECH), Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"},{"name":"Department of Otolaryngology, College of Medicine, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Hincapie-Castillo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut G.","family":"Winterstein","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville"},{"name":"Center for Drug Evaluation and Safety, University of Florida, Gainesville"},{"name":"Department of Epidemiology, College of Public Health and Health Professions, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"ioi210013r1","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone antibiotics.","volume":"10","author":"Pham","year":"2019","journal-title":"Medchemcomm"},{"issue":"5","key":"ioi210013r2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of quinolone action and resistance: where do we stand?","volume":"66","author":"Correia","year":"2017","journal-title":"J Med Microbiol"},{"issue":"6","key":"ioi210013r3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1213\/XAA.0000000000000769","article-title":"Spinal cord neuromodulation therapy for levofloxacin-reinduced complex regional pain syndrome and neurotoxicity: a case report.","volume":"11","author":"Hao","year":"2018","journal-title":"A A Pract"},{"issue":"4","key":"ioi210013r4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s12325-017-0514-y","article-title":"The impact of antibiotic stewardship programs in combating quinolone resistance: a systematic review and recommendations for more efficient interventions.","volume":"34","author":"Pitiriga","year":"2017","journal-title":"Advances in Therapy"},{"issue":"3","key":"ioi210013r5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.amjmed.2004.09.015","article-title":"Fluoroquinolone prescribing in the United States: 1995 to 2002.","volume":"118","author":"Linder","year":"2005","journal-title":"Am J Med"},{"issue":"5","key":"ioi210013r8","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"9","key":"ioi210013r9","first-page":"1057","article-title":"Acute rhinosinusitis in Adults.","volume":"83","author":"Aring","year":"2011","journal-title":"American Family Physician"},{"issue":"8","key":"ioi210013r10","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1093\/cid\/cis370","article-title":"IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.","volume":"54","author":"Chow","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ioi210013r11","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/0194599815574247","article-title":"Clinical practice guideline (update): Adult Sinusitis Executive Summary.","volume":"152","author":"Rosenfeld","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"ioi210013r14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1056\/NEJM199501193320319","article-title":"More on fluoroquinolone antibiotics and tendon rupture.","volume":"332","author":"Szarfman","year":"1995","journal-title":"N Engl J Med"},{"issue":"10","key":"ioi210013r15","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00228-019-02713-1","article-title":"Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis.","volume":"75","author":"Alves","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"ioi210013r16","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix362","article-title":"Fluoroquinolone use and risk of carpal tunnel syndrome: a pharmacoepidemiologic study.","author":"Cheng","year":"2017"},{"issue":"14","key":"ioi210013r17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/WNL.0000000000000846","article-title":"Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study.","volume":"83","author":"Etminan","year":"2014","journal-title":"Neurology"},{"key":"ioi210013r18","doi-asserted-by":"publisher","first-page":"k678","DOI":"10.1136\/bmj.k678","article-title":"Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study.","volume":"360","author":"Pasternak","year":"2018","journal-title":"BMJ"},{"issue":"11","key":"ioi210013r19","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1001\/jamainternmed.2015.5389","article-title":"Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone.","volume":"175","author":"Lee","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"11","key":"ioi210013r21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1017\/ice.2019.247","article-title":"Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals.","volume":"40","author":"Yarrington","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"ioi210013r22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/pds.v29.6","article-title":"Outpatient fluoroquinolone prescribing patterns before and after US FDA boxed warning.","volume":"29","author":"Bratsman","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"ioi210013r23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy198","article-title":"An Assessment of Inappropriate Antibiotic Use and Guideline Adherence for Uncomplicated Urinary Tract Infections.","volume":"5","author":"Durkin","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"ioi210013r24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146822","article-title":"Identification of Medicare recipients at highest risk for clostridium difficile infection in the US by population attributable risk analysis.","volume":"11","author":"Dubberke","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"ioi210013r25","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/alr.2016.6.issue-11","article-title":"A validated case definition for chronic rhinosinusitis in administrative data: a Canadian perspective.","volume":"6","author":"Rudmik","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"ioi210013r26","first-page":"58","article-title":"External validation of a COPD risk measure in a commercial and Medicare population: the COPD treatment ratio.","volume":"25","author":"Stanford","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"ioi210013r27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1513\/AnnalsATS.201508-493OC","article-title":"Validation of a new risk measure for chronic obstructive pulmonary disease exacerbation using health insurance claims data.","volume":"13","author":"Stanford","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"ioi210013r31","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2214-109X(17)30078-5","article-title":"Effect of Ebola virus disease on maternal and child health services in Guinea: a retrospective observational cohort study.","volume":"5","author":"Delamou","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"8","key":"ioi210013r32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","article-title":"Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations.","volume":"68","author":"Jandoc","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"ioi210013r33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"ioi210013r34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/0194599819889607","article-title":"Appropriateness of otic quinolone use among privately insured US patients.","volume":"162","author":"Tran","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"17","key":"ioi210013r35","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016.","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"issue":"15","key":"ioi210013r36","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1001\/archinternmed.2010.253","article-title":"Spectrum of cancer risk late after AIDS onset in the United States.","volume":"170","author":"Simard","year":"2010","journal-title":"Arch Intern Med"},{"issue":"7","key":"ioi210013r37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8090","article-title":"National trends in colorectal cancer incidence among older and younger adults in Canada.","volume":"2","author":"Brenner","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"ioi210013r38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/pds.3894","article-title":"Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides.","volume":"25","author":"Chen","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"ioi210013r41","first-page":"1308","article-title":"US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011.","volume":"60","author":"Hicks","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"ioi210013r42","article-title":"Factors affecting adherence to evidence-based guidelines in the treatment of URI, sinusitis, and pharyngitis.","volume":"3","author":"Crocker","year":"2013","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ioi210013r6","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Accessed 10 Mar, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics"},{"key":"ioi210013r7","unstructured":"US Food and Drug Administration. Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. Accessed June 23, 2020. http:\/\/wayback.archive-it.org\/7993\/20170112032310\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm126085.htm"},{"key":"ioi210013r12","unstructured":"US Department of Veterans Affairs. VA\/DOD Clinical Practice Guideline. Management of Outpatient Chronic Obstructive Pulmonary Disease. Accessed March 26, 2020. https:\/\/www.healthquality.va.gov\/guidelines\/CD\/copd\/VADoDCOPDCPG2014.pdf"},{"key":"ioi210013r13","unstructured":"US Food and Drug Administration. Summary Minutes of the Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Risk and Safety Management Advisory Committee November 5, 2015. Accessed June 23, 2020. http:\/\/wayback.archive-it.org\/7993\/20170113044503\/http:\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM475246.pdf"},{"key":"ioi210013r20","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Accessed June 23, 2020. https:\/\/www.fda.gov\/media\/97602\/download"},{"key":"ioi210013r28","unstructured":"Hooton? T, Gupta? K. Acute simple cystitis in women. Accessed Mar 17, 2020. https:\/\/www.uptodate.com\/contents\/acute-simple-cystitis-in-women#H207461713"},{"key":"ioi210013r29","unstructured":"Patel? Z, Hwang? P. Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment. Accessed Mar 17, 2020. https:\/\/www.uptodate.com\/contents\/uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment#H17857080"},{"key":"ioi210013r30","unstructured":"Sethi? S, Murphy? T. Management of infection in exacerbations of chronic obstructive pulmonary disease. 2020; https:\/\/www.uptodate.com\/contents\/management-of-infection-in-exacerbations-of-chronic-obstructive-pulmonary-disease. Accessed Mar 17, 2020."},{"key":"ioi210013r39","unstructured":"US Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Accessed Jan 3, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics"},{"key":"ioi210013r40","unstructured":"US Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics requires label changes. Accessed Jan 3, 2020. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2778964\/jamainternal_tran_2021_oi_210013_1622845419.41843.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T16:05:30Z","timestamp":1623081930000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2778964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2021.1154","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}